Teva Pharmaceutical Industries Ltd.

Director's Dealing • Mar 6, 2024

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(th) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Kalif Eliyahu Sharon	2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below) EVP, Chief Financial Officer
Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	3. Date of Earliest Transaction (Month/Day/Year) 03/03/2024
(Street) Tel Aviv, L3 6944020	4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (Zip) (State)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security	2. Transaction	2A. Deemed	3. Transaction		4. Securities Acquired			5. Amount of Securities Beneficially		7. Nature
(Instr. 3)	Date	l Execution Date, if Code			(A) or Disposed of (D)			Owned Following Reported	Ownership of Indirect
	(Month/Day/Year) any		(Instr. 8)		(Instr. 3, 4 and 5)			Transaction(s)	Form:	Beneficial
		ا (Month/Day/Year)						(Instr. 3 and 4)		Direct (D) Ownership
									or Indirect (Instr. 4)
						(A) or			(1)
			Code		Amount	D)	Price		(Instr. 4)
'Ordinary Shares (1)	03/03/2024		M		49,800	A	(2)	174.022	D
'Ordinary Shares (1)	03/04/2024		M		33,512	A	(2)	207,534	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2 Conversion Date Price of Derivative Security	3. Transaction or Exercise (Month/Day/Year) any	3A. Deemed Execution Date, if Transaction Derivative (Month/Day/Year) (Instr. 8)	4. Code	5. Number of Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Security (Instr. 5)	8. Price of 9. Number of Derivative Derivative Securities Beneficially Owned Following	10 Form of Derivative Security: Direct (D)	11. Nature Ownership of Indirect Beneficial Ownership (Instr. 4)
				Code	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	or Indirect (D) (Instr. 4)
Restricted Share Units	(2)	03/03/2024		M		49,800	(3)	(3)	Ordinary Shares (1)	49,800	\$ 0	174,022	D
Restricted Share Units	(2)	03/04/2024		M		33,512	(4)	(4)	Ordinary Shares (1)	33,512	\$ 0	207,534	D
Restricted Share Units	(2)	03/04/2024		A	93,005		(5)	(5)	Ordinary Shares (1)	93,005	\$ 0	93,005	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. 1. Each restricted share unit represents a continent, one or the opten of the Himan Resources and Compensation Committee, the cast value of one ordinary share.
3. 1. Restricted share units were granted on March 3, 2024, March 3, 2024, March 3, 2024, March 3, 2026, and 49,802 vesing on March 3, 2027.
4. 1. Restricted share units were grantel on March 4, 2022, with 3,512 vested on March 4, 2024, and 3,512 vesting on each of March 4, 2026,
5. 1. Restincted share were granted on March 4, 2024, with 23,251 vesting on each of March 4, 2025, March 4, 2021, and 23,212 vesting on March 4, 2028,

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif 03/05/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly.

• * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
• ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 18tf(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of in this form are not required to respond unless the form displays a currently valid OMB Number.